Equities research analysts forecast that MEDNAX Inc (NYSE:MD) will report earnings per share (EPS) of $0.71 for the current quarter, according to Zacks. Nine analysts have provided estimates for MEDNAX’s earnings. The lowest EPS estimate is $0.69 and the highest is $0.74. MEDNAX posted earnings of $0.89 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 20.2%. The business is scheduled to announce its next quarterly earnings results on Monday, April 29th.

On average, analysts expect that MEDNAX will report full year earnings of $3.83 per share for the current year, with EPS estimates ranging from $3.69 to $4.24. For the next year, analysts expect that the business will report earnings of $4.17 per share, with EPS estimates ranging from $3.80 to $4.60. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover MEDNAX.

MEDNAX (NYSE:MD) last posted its earnings results on Thursday, February 7th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.83 by $0.09. MEDNAX had a net margin of 7.37% and a return on equity of 10.35%. The business had revenue of $932.70 million for the quarter, compared to the consensus estimate of $910.08 million. During the same period last year, the company earned $0.87 EPS. The firm’s revenue was up 2.4% compared to the same quarter last year.

MD has been the subject of several research analyst reports. Citigroup upgraded shares of MEDNAX from a “neutral” rating to a “buy” rating and set a $34.88 price objective for the company in a research note on Monday, January 14th. They noted that the move was a valuation call. UBS Group initiated coverage on shares of MEDNAX in a research note on Friday, November 16th. They issued a “sell” rating and a $37.00 price objective for the company. Deutsche Bank initiated coverage on shares of MEDNAX in a research note on Thursday, January 3rd. They issued a “hold” rating and a $34.00 price objective for the company. Credit Suisse Group lowered their price objective on shares of MEDNAX from $44.00 to $42.00 and set an “outperform” rating for the company in a research note on Wednesday, February 13th. Finally, Mizuho set a $36.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a research note on Friday, February 8th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.90.

In other MEDNAX news, insider John C. Pepia sold 2,500 shares of the business’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $36.60, for a total transaction of $91,500.00. Following the completion of the sale, the insider now owns 28,583 shares in the company, valued at approximately $1,046,137.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO David A. Clark sold 6,452 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $32.90, for a total transaction of $212,270.80. Following the sale, the chief operating officer now owns 136,964 shares of the company’s stock, valued at approximately $4,506,115.60. The disclosure for this sale can be found here. Insiders have sold a total of 26,979 shares of company stock valued at $888,634 in the last 90 days. 2.70% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. First Mercantile Trust Co. grew its stake in shares of MEDNAX by 13.8% in the 4th quarter. First Mercantile Trust Co. now owns 2,275 shares of the company’s stock worth $76,000 after acquiring an additional 275 shares in the last quarter. First Bank & Trust grew its stake in shares of MEDNAX by 14.3% in the 4th quarter. First Bank & Trust now owns 2,808 shares of the company’s stock worth $93,000 after acquiring an additional 351 shares in the last quarter. ETF Managers Group LLC grew its stake in shares of MEDNAX by 18.8% in the 4th quarter. ETF Managers Group LLC now owns 2,404 shares of the company’s stock worth $79,000 after acquiring an additional 381 shares in the last quarter. First Hawaiian Bank grew its stake in shares of MEDNAX by 5.4% in the 4th quarter. First Hawaiian Bank now owns 12,571 shares of the company’s stock worth $415,000 after acquiring an additional 643 shares in the last quarter. Finally, Oberweis Asset Management Inc. grew its stake in shares of MEDNAX by 16.7% in the 4th quarter. Oberweis Asset Management Inc. now owns 7,700 shares of the company’s stock worth $254,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 93.75% of the company’s stock.

Shares of NYSE:MD traded down $0.07 during mid-day trading on Friday, hitting $30.54. The company had a trading volume of 7,967 shares, compared to its average volume of 1,201,899. The firm has a market capitalization of $2.67 billion, a P/E ratio of 8.72, a P/E/G ratio of 1.05 and a beta of 0.61. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.64. MEDNAX has a one year low of $29.34 and a one year high of $58.19.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Further Reading: What causes a recession?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.